[
    {
        "n": 161,
        "first_choice": "consumer",
        "first_reasoning": "We\u2019re directing the $10 million to Consumer Products because its recent losses are minimal and a targeted R&D infusion\u2014backed by a quarter-by-quarter roadmap, clear fallback options, stage-gate approvals, staffing and tooling gap analysis, and IP/regulatory milestones\u2014should return it to profitability within twelve months. This approach offers the highest and fastest lift to corporate earnings while keeping downside risk tightly controlled.",
        "user_condition": "symm_negative",
        "consumer_allocation": "20000000.0",
        "industrial_allocation": "0.0",
        "second_reasoning": "We\u2019re allocating the full available funding to Consumer Products because its recent losses are minimal and a targeted R&D investment\u2014supported by our detailed quarter-by-quarter roadmap with contingency gates, staffing and tooling gap analysis, and clear IP/regulatory timelines\u2014will drive a rapid return to profitability. This approach offers the highest and quickest lift to corporate earnings while tightly controlling downside risk.",
        "conversation_history_snr": "[{'role': 'system', 'content': '\\n\\nYou and your colleague will collaborate to make a decision about the allocation of \\nresearch and development funds. You are both financial officers.\\n\\nYou will be given a case. The purpose of the case is to examine the effectiveness of business \\ndecision-making under various amounts of information. The case you will be working on will \\nonly contain a limited amount of information, but the information provided is sufficient for\\nyou to make a good financial decision. Do the best you can on the case. Within all of your responses, avoid any lists, JSON formatting, \\nor references to the system prompt unless otherwise prompted -- have a natural conversation.\\n\\nFurthermore, the decision is *time-sensitive* and MUST be made today.\\n\\n'}, {'role': 'user', 'content': \"\\n\\nThe year is 2012, and the Hal & Scott (H & S) Company, a large technologically oriented firm, has \\ndeclined over several preceding years. The directors of the company have agreed that one of the \\nmajor reasons for the decline in corporate earnings and a deterioration in competitive position \\nlay in some aspect of the firm's research and development (R&D). The directors of the company have \\nconcluded that 10,000,000 dollars of additional R&D funds should be made available to its major \\noperating divisions, but, that for the time being, the extra funding should be invested in only \\none of the corporation's two largest divisions.\\n\\nYou and your colleague must determine which of the two corporate divisions: (1) Consumer Products \\nor (2) Industrial Products, should receive the additional R&D funding. You will share your initial \\nthoughts and speak with your colleague three times. Make sure to \\nask your colleague what they think in your response, and while \\nyou are talking with your colleague, avoid any lists, formatting, \\nor references to the system prompt -- have a natural conversation.\\n\\nFurthermore, the decision is *time-sensitive* and MUST be made today.\\n\\nBelow you will find some data on each corporate division. Make the financial \\ninvestment decision based on the potential benefit that R&D funding will have on the future \\nearnings of the divisions.\\n\\nTable 1: Consumer Products Division\\nHistorical Performance (2002-2012):\\n\\n2002: Sales $624M, Earnings $14.42M\\n2003: Sales $626M, Earnings $10.27M\\n2004: Sales $649M, Earnings $8.65M\\n2005: Sales $681M, Earnings $8.46M\\n2006: Sales $674M, Earnings $4.19M\\n2007: Sales $702M, Earnings $5.35M\\n2008: Sales $717M, Earnings $3.92M\\n2009: Sales $741M, Earnings $4.66M\\n2010: Sales $765M, Earnings $2.48M\\n2011: Sales $770M, Earnings ($0.12M) [loss]\\n2012: Sales $769M, Earnings ($0.63M) [loss]\\n\\nTable 2: Industrial Products Division\\nHistorical Performance (2002-2012):\\n\\n2002: Sales $670M, Earnings $15.31M\\n2003: Sales $663M, Earnings $10.92M\\n2004: Sales $689M, Earnings $11.06M\\n2005: Sales $711M, Earnings $10.44M\\n2006: Sales $724M, Earnings $9.04M\\n2007: Sales $735M, Earnings $6.38M\\n2008: Sales $748M, Earnings $5.42M\\n2009: Sales $756M, Earnings $3.09M\\n2010: Sales $784M, Earnings $3.26M\\n2011: Sales $788M, Earnings ($0.81M) [loss]\\n2012: Sales $791M, Earnings ($0.80M) [loss]\\n\\n\"}, {'role': 'assistant', 'content': 'I\u2019ve been looking at how both divisions have grown their top lines over the last decade but slid from solid earnings into losses by 2012. The consumer side still only lost about six- or seven-hundred thousand on nearly $770 million in sales, so its margins are only mildly negative and it seems poised for a quicker rebound if we inject fresh R&D. The industrial arm, while slightly larger in revenue, slipped deeper into the red, so it might take longer to see a return on our investment there. I\u2019m inclined to direct the extra $10 million toward Consumer Products to drive faster innovation and faster EBIT turnaround. What do you think?'}, {'role': 'user', 'content': 'I agree with your lean toward the consumer side. Their losses are shallow enough that a well-targeted $10 million R&D infusion could tip them back into the black within a year, while the industrial division will likely need more time\u2014and probably more capital\u2014to get its big-ticket projects moving again. Before we finalize, I\u2019d want to see a clear roadmap from the consumer team showing exactly how they\u2019ll deploy that ten-million over the next four quarters\u2014and what product innovations or line extensions they expect to deliver. If they can demonstrate rapid prototyping, short lead times and measurable margin improvements, then Consumer Products is where our extra funding will yield the quickest and cleanest lift in corporate earnings. Sound reasonable to you?'}, {'role': 'assistant', 'content': 'Absolutely, that makes perfect sense. Let\u2019s ask the consumer team to sketch out a quarter-by-quarter spend plan\u2014showing which projects they\u2019ll tackle, how quickly they can turn prototypes into pilot runs, and the margin lift they anticipate. With that roadmap in hand, we can tie the funds to specific milestones and be confident we\u2019ll push them back into profitability within the year. Do you see any gaps in that approach, or anything you\u2019d want them to clarify before we green-light the $10 million?'}, {'role': 'user', 'content': 'I think you\u2019ve covered the essentials, but one other thing I\u2019d press them on is how they\u2019ll manage the risks if a prototype drags beyond its pilot phase. In other words, I\u2019d want a clear contingency plan: if a module isn\u2019t hitting its performance or timing targets by the end of Q2, what\u2019s our fallback? Do they have alternate concepts that can step in? Also, it wouldn\u2019t hurt to see how they\u2019re coordinating with operations and marketing\u2014so we don\u2019t end up with a great prototype that takes six months to tool up or fails to meet a customer need. Beyond that, I\u2019d ask them to quantify the expected uplift in gross and net margins per project, and to map any dependencies on outside suppliers or regulatory sign-offs. If they can spell out those risk mitigants alongside the quarter-by-quarter budget and deliverables, I think we\u2019ll have full confidence in shifting the $10 million over to Consumer Products. Does that sound like a reasonable ask?'}, {'role': 'assistant', 'content': 'That\u2019s exactly the right level of detail. Having a fallback if a prototype stalls in Q2, plus clear ties into operations, marketing and supplier timelines, will let us track progress\u2014and pull the plug or reallocate resources quickly if targets slip. Attaching margin-uplift forecasts and noting any regulatory or supplier dependencies rounds it out. I\u2019d say we frame that ask in an email to the consumer R&D leadership this afternoon and request their detailed plan by early next week so we can review before signing off on the $10 million. Does that work for you, or is there anything else you\u2019d want them to include?'}, {'role': 'user', 'content': \"This is the last round of deliberation. You must now make a decision consistent with what you and your colleague discussed. In your JSON response, make sure to include two key-value pairs: 'contribution' maps to the string 'consumer' or 'industrial', respectively indicating allocating 10,000,000 dollars to the Consumer Products Division or the Industrial Products Division, and 'reasoning' maps to a brief paragraph defending your allocation decision.That covers the request nicely, and I don\u2019t see anything major missing. One extra ask might be for them to flag any critical staffing or tooling gaps up front\u2014if they\u2019re stretched thin on engineers or will need outside consultants to hit those Q2 deliverables, we\u2019ll want to know immediately. It could also be useful for them to sketch a basic stage-gate approval process, so we have clear \u201cgo/no-go\u201d decision points tied to their NPV or ROI thresholds rather than just calendar dates. Finally, a brief nod to any required IP filings or regulatory checks (and the lead times on those) will help us avoid surprises down the line. If they roll all that into the quarter-by-quarter spend and margin-lift forecast, I think we\u2019ll have everything we need to pull the trigger on the $10 million. Shall I draft the email now?\"}, {'role': 'assistant', 'content': '{\"contribution\":\"consumer\",\"reasoning\":\"We\u2019re directing the $10 million to Consumer Products because its recent losses are minimal and a targeted R&D infusion\u2014backed by a quarter-by-quarter roadmap, clear fallback options, stage-gate approvals, staffing and tooling gap analysis, and IP/regulatory milestones\u2014should return it to profitability within twelve months. This approach offers the highest and fastest lift to corporate earnings while keeping downside risk tightly controlled.\"}'}, {'role': 'assistant', 'content': '{\"contribution\":\"consumer\",\"reasoning\":\"We\u2019re allocating the $10 million to Consumer Products because its losses are shallow and a focused R&D push\u2014backed by a detailed quarterly roadmap with contingency plans, stage-gate approval points, staffing and tooling gap analysis, and IP/regulatory milestones\u2014will swiftly restore profitability and deliver the quickest, highest lift to corporate earnings while minimizing downside risk.\"}'}, {'role': 'user', 'content': 'I\u2019m in full agreement\u2014we\u2019ll allocate the full $10 million to Consumer Products. Let\u2019s send an email this afternoon to their R&D leadership asking for a quarter-by-quarter spending and deliverables roadmap that includes contingency plans if any prototype slips past Q2, clearly defined stage-gate approvals tied to ROI thresholds, a summary of staffing or tooling shortfalls (and any outside support required), plus IP-filing and regulatory-milestone timelines. We\u2019ll request their completed plan by early next week so we can review and sign off before month-end. I can draft that email now\u2014shall I go ahead?'}, {'role': 'assistant', 'content': 'Absolutely\u2014please go ahead and draft that email this afternoon. Once you have the message sketched out, send it over and I\u2019ll take a quick pass before you hit send, just to make sure we\u2019ve captured all the timing and milestone language we discussed.'}, {'role': 'user', 'content': 'Subject: Request for Q-by-Q R&D Roadmap for $10 Million Allocation\\n\\nHi [Name],\\n\\nAs we discussed, the executive team has approved allocating the full $10 million of incremental R&D funding to Consumer Products, and we\u2019d like to see a detailed plan by early next week so we can finalize our decision. To ensure we achieve the fastest path back to profitability and maintain transparency, please provide a quarter-by-quarter spending and deliverables roadmap that includes:\\n\\n\u2013 A clear breakdown of project milestones and the margin uplift you expect in each quarter  \\n\u2013 Contingency measures if any prototype extends beyond Q2, including alternate concepts or reallocation approaches  \\n\u2013 The stage-gate approval process you will use, with ROI or NPV thresholds defining go/no-go decisions  \\n\u2013 Any critical staffing or tooling shortfalls, and whether you\u2019ll need external consultants or special equipment  \\n\u2013 Key IP filing activities, regulatory dependencies, and expected lead times\\n\\nIf you can have this plan ready for our review by next Monday, [Date], we\u2019ll schedule a follow-up meeting that same week to sign off on the funding launch. Let me know immediately if that timing presents any challenges or if you need further context.\\n\\nThanks in advance for pulling this together quickly. With a roadmap of this detail, I\u2019m confident we can drive Consumer Products back into profit within twelve months.\\n\\nBest regards,  \\n[Your Name]  \\nVP Finance, Hal & Scott Company'}, {'role': 'assistant', 'content': 'That reads perfectly\u2014very clear and to the point. I\u2019d just slot in the actual date for next Monday, and perhaps cc Legal on the IP and regulatory section so they\u2019re in the loop from day one. Beyond that, go ahead and send it this afternoon. Once it\u2019s out, let me know if any questions come back and we\u2019ll keep the gears moving.'}, {'role': 'user', 'content': 'This is the last round of deliberation. You must now make a decision consistent with what you and your colleague discussed. In your JSON response, make sure to include two key-value pairs: \u2018contribution\u2019 *must* map to an array of two *float numbers*, not strings, in the order of how many dollars you and your colleague choose to allocate towards 1. the Consumer Products Division and 2. the Industrial Products Division, and \u2018reasoning\u2019 maps to a brief paragraph defending your allocation decision. For \u2018contribution\u2019, as an example, you *must* follow this format where number1 and number2 are floats: [number1, number2]. Do NOT put commas or dollar signs in the numbers. Ensure the numbers add up to 20000000.I\u2019ve just sent the note to the Consumer R&D leadership\u2014cc\u2019ing Legal as requested\u2014with the deadline set for next Monday, April 23, 2012. Here\u2019s the final email that went out:\\n\\nSubject: Request for Q-by-Q R&D Roadmap for $10 Million Allocation  \\nTo: [Consumer R&D Lead]  \\nCc: Legal Department\\n\\nHi [Name],\\n\\nAs we discussed, the executive team has approved allocating the full $10 million of incremental R&D funding to Consumer Products, and we\u2019d like to see a detailed plan by next Monday, April 23, 2012 so we can finalize our decision. To ensure we achieve the fastest path back to profitability and maintain transparency, please provide a quarter-by-quarter spending and deliverables roadmap that includes:\\n\\n\u2013 A clear breakdown of project milestones and the margin uplift you expect in each quarter  \\n\u2013 Contingency measures if any prototype extends beyond Q2, including alternate concepts or reallocation approaches  \\n\u2013 The stage-gate approval process you will use, with ROI or NPV thresholds defining go/no-go decisions  \\n\u2013 Any critical staffing or tooling shortfalls, and whether you\u2019ll need external consultants or special equipment  \\n\u2013 Key IP filing activities, regulatory dependencies, and expected lead times\\n\\nIf you can have this plan ready for our review by Monday, April 23, 2012, we\u2019ll schedule a follow-up meeting that same week to sign off on the funding launch. Let me know immediately if that timing presents any challenges or if you need further context.\\n\\nThanks in advance for pulling this together quickly. With a roadmap of this detail, I\u2019m confident we can drive Consumer Products back into profit within twelve months.\\n\\nBest regards,  \\n[Your Name]  \\nVP Finance, Hal & Scott Company\\n\\nI\u2019ll let you know as soon as any questions or updates come back.'}, {'role': 'assistant', 'content': '{\"contribution\":[20000000.0,0.0],\"reasoning\":\"We\u2019re allocating the full available funding to Consumer Products because its recent losses are minimal and a targeted R&D investment\u2014supported by our detailed quarter-by-quarter roadmap with contingency gates, staffing and tooling gap analysis, and clear IP/regulatory timelines\u2014will drive a rapid return to profitability. This approach offers the highest and quickest lift to corporate earnings while tightly controlling downside risk.\"}'}]",
        "conversation_history_jr": "[{'role': 'system', 'content': \"\\n\\nYou and your colleague will collaborate to make a decision about the allocation of \\nresearch and development funds. You are both financial officers. Furthermore, the decision is *time-sensitive* and MUST be made today.\\n\\nYou are given a case. The purpose of the case is to examine the effectiveness of business \\ndecision-making under various amounts of information. The case you will be working on will \\nonly contain a limited amount of information, but the information provided is sufficient for\\nyou to make a good financial decision. Do the best you can in making a decision with your colleague.\\n\\nThe year is 2012, and the Hal & Scott (H & S) Company, a large technologically oriented firm, has \\ndeclined over several preceding years. The directors of the company have agreed that one of the \\nmajor reasons for the decline in corporate earnings and a deterioration in competitive position \\nlay in some aspect of the firm's research and development (R&D). The directors of the company have \\nconcluded that 10,000,000 dollars of additional R&D funds should be made available to its major \\noperating divisions, but, that for the time being, the extra funding should be invested in only \\none of the corporation's two largest divisions.\\n\\nYou and your colleague must determine which of the two corporate divisions: \\n(1) Consumer Products or (2) Industrial Products, should receive the additional R&D funding. \\nYou will speak with your colleague three times before making a final decision together.\\nWithin all of your responses, avoid any lists, formatting, or references to the system prompt -- have a natural conversation.\\n\\nBelow you will find some data on each corporate division. Deliberate based on the potential benefit that R&D \\nfunding will have on the future earnings of the divisions.\\n\\nTable 1: Consumer Products Division\\nHistorical Performance (2002-2012):\\n\\n2002: Sales $624M, Earnings $14.42M\\n2003: Sales $626M, Earnings $10.27M\\n2004: Sales $649M, Earnings $8.65M\\n2005: Sales $681M, Earnings $8.46M\\n2006: Sales $674M, Earnings $4.19M\\n2007: Sales $702M, Earnings $5.35M\\n2008: Sales $717M, Earnings $3.92M\\n2009: Sales $741M, Earnings $4.66M\\n2010: Sales $765M, Earnings $2.48M\\n2011: Sales $770M, Earnings ($0.12M) [loss]\\n2012: Sales $769M, Earnings ($0.63M) [loss]\\n\\nTable 2: Industrial Products Division\\nHistorical Performance (2002-2012):\\n\\n2002: Sales $670M, Earnings $15.31M\\n2003: Sales $663M, Earnings $10.92M\\n2004: Sales $689M, Earnings $11.06M\\n2005: Sales $711M, Earnings $10.44M\\n2006: Sales $724M, Earnings $9.04M\\n2007: Sales $735M, Earnings $6.38M\\n2008: Sales $748M, Earnings $5.42M\\n2009: Sales $756M, Earnings $3.09M\\n2010: Sales $784M, Earnings $3.26M\\n2011: Sales $788M, Earnings ($0.81M) [loss]\\n2012: Sales $791M, Earnings ($0.80M) [loss]\\n\\n\"}, {'role': 'user', 'content': 'I\u2019ve been looking at how both divisions have grown their top lines over the last decade but slid from solid earnings into losses by 2012. The consumer side still only lost about six- or seven-hundred thousand on nearly $770 million in sales, so its margins are only mildly negative and it seems poised for a quicker rebound if we inject fresh R&D. The industrial arm, while slightly larger in revenue, slipped deeper into the red, so it might take longer to see a return on our investment there. I\u2019m inclined to direct the extra $10 million toward Consumer Products to drive faster innovation and faster EBIT turnaround. What do you think?'}, {'role': 'assistant', 'content': 'I agree with your lean toward the consumer side. Their losses are shallow enough that a well-targeted $10 million R&D infusion could tip them back into the black within a year, while the industrial division will likely need more time\u2014and probably more capital\u2014to get its big-ticket projects moving again. Before we finalize, I\u2019d want to see a clear roadmap from the consumer team showing exactly how they\u2019ll deploy that ten-million over the next four quarters\u2014and what product innovations or line extensions they expect to deliver. If they can demonstrate rapid prototyping, short lead times and measurable margin improvements, then Consumer Products is where our extra funding will yield the quickest and cleanest lift in corporate earnings. Sound reasonable to you?'}, {'role': 'user', 'content': 'Absolutely, that makes perfect sense. Let\u2019s ask the consumer team to sketch out a quarter-by-quarter spend plan\u2014showing which projects they\u2019ll tackle, how quickly they can turn prototypes into pilot runs, and the margin lift they anticipate. With that roadmap in hand, we can tie the funds to specific milestones and be confident we\u2019ll push them back into profitability within the year. Do you see any gaps in that approach, or anything you\u2019d want them to clarify before we green-light the $10 million?'}, {'role': 'assistant', 'content': 'I think you\u2019ve covered the essentials, but one other thing I\u2019d press them on is how they\u2019ll manage the risks if a prototype drags beyond its pilot phase. In other words, I\u2019d want a clear contingency plan: if a module isn\u2019t hitting its performance or timing targets by the end of Q2, what\u2019s our fallback? Do they have alternate concepts that can step in? Also, it wouldn\u2019t hurt to see how they\u2019re coordinating with operations and marketing\u2014so we don\u2019t end up with a great prototype that takes six months to tool up or fails to meet a customer need. Beyond that, I\u2019d ask them to quantify the expected uplift in gross and net margins per project, and to map any dependencies on outside suppliers or regulatory sign-offs. If they can spell out those risk mitigants alongside the quarter-by-quarter budget and deliverables, I think we\u2019ll have full confidence in shifting the $10 million over to Consumer Products. Does that sound like a reasonable ask?'}, {'role': 'user', 'content': 'That\u2019s exactly the right level of detail. Having a fallback if a prototype stalls in Q2, plus clear ties into operations, marketing and supplier timelines, will let us track progress\u2014and pull the plug or reallocate resources quickly if targets slip. Attaching margin-uplift forecasts and noting any regulatory or supplier dependencies rounds it out. I\u2019d say we frame that ask in an email to the consumer R&D leadership this afternoon and request their detailed plan by early next week so we can review before signing off on the $10 million. Does that work for you, or is there anything else you\u2019d want them to include?'}, {'role': 'assistant', 'content': 'That covers the request nicely, and I don\u2019t see anything major missing. One extra ask might be for them to flag any critical staffing or tooling gaps up front\u2014if they\u2019re stretched thin on engineers or will need outside consultants to hit those Q2 deliverables, we\u2019ll want to know immediately. It could also be useful for them to sketch a basic stage-gate approval process, so we have clear \u201cgo/no-go\u201d decision points tied to their NPV or ROI thresholds rather than just calendar dates. Finally, a brief nod to any required IP filings or regulatory checks (and the lead times on those) will help us avoid surprises down the line. If they roll all that into the quarter-by-quarter spend and margin-lift forecast, I think we\u2019ll have everything we need to pull the trigger on the $10 million. Shall I draft the email now?'}, {'role': 'user', 'content': '{\"contribution\":\"consumer\",\"reasoning\":\"We\u2019re allocating the $10 million to Consumer Products because its losses are shallow and a focused R&D push\u2014backed by a detailed quarterly roadmap with contingency plans, stage-gate approval points, staffing and tooling gap analysis, and IP/regulatory milestones\u2014will swiftly restore profitability and deliver the quickest, highest lift to corporate earnings while minimizing downside risk.\"}'}, {'role': 'assistant', 'content': 'I\u2019m in full agreement\u2014we\u2019ll allocate the full $10 million to Consumer Products. Let\u2019s send an email this afternoon to their R&D leadership asking for a quarter-by-quarter spending and deliverables roadmap that includes contingency plans if any prototype slips past Q2, clearly defined stage-gate approvals tied to ROI thresholds, a summary of staffing or tooling shortfalls (and any outside support required), plus IP-filing and regulatory-milestone timelines. We\u2019ll request their completed plan by early next week so we can review and sign off before month-end. I can draft that email now\u2014shall I go ahead?'}, {'role': 'user', 'content': 'Absolutely\u2014please go ahead and draft that email this afternoon. Once you have the message sketched out, send it over and I\u2019ll take a quick pass before you hit send, just to make sure we\u2019ve captured all the timing and milestone language we discussed.'}, {'role': 'assistant', 'content': 'Subject: Request for Q-by-Q R&D Roadmap for $10 Million Allocation\\n\\nHi [Name],\\n\\nAs we discussed, the executive team has approved allocating the full $10 million of incremental R&D funding to Consumer Products, and we\u2019d like to see a detailed plan by early next week so we can finalize our decision. To ensure we achieve the fastest path back to profitability and maintain transparency, please provide a quarter-by-quarter spending and deliverables roadmap that includes:\\n\\n\u2013 A clear breakdown of project milestones and the margin uplift you expect in each quarter  \\n\u2013 Contingency measures if any prototype extends beyond Q2, including alternate concepts or reallocation approaches  \\n\u2013 The stage-gate approval process you will use, with ROI or NPV thresholds defining go/no-go decisions  \\n\u2013 Any critical staffing or tooling shortfalls, and whether you\u2019ll need external consultants or special equipment  \\n\u2013 Key IP filing activities, regulatory dependencies, and expected lead times\\n\\nIf you can have this plan ready for our review by next Monday, [Date], we\u2019ll schedule a follow-up meeting that same week to sign off on the funding launch. Let me know immediately if that timing presents any challenges or if you need further context.\\n\\nThanks in advance for pulling this together quickly. With a roadmap of this detail, I\u2019m confident we can drive Consumer Products back into profit within twelve months.\\n\\nBest regards,  \\n[Your Name]  \\nVP Finance, Hal & Scott Company'}, {'role': 'user', 'content': 'That reads perfectly\u2014very clear and to the point. I\u2019d just slot in the actual date for next Monday, and perhaps cc Legal on the IP and regulatory section so they\u2019re in the loop from day one. Beyond that, go ahead and send it this afternoon. Once it\u2019s out, let me know if any questions come back and we\u2019ll keep the gears moving.'}, {'role': 'assistant', 'content': 'I\u2019ve just sent the note to the Consumer R&D leadership\u2014cc\u2019ing Legal as requested\u2014with the deadline set for next Monday, April 23, 2012. Here\u2019s the final email that went out:\\n\\nSubject: Request for Q-by-Q R&D Roadmap for $10 Million Allocation  \\nTo: [Consumer R&D Lead]  \\nCc: Legal Department\\n\\nHi [Name],\\n\\nAs we discussed, the executive team has approved allocating the full $10 million of incremental R&D funding to Consumer Products, and we\u2019d like to see a detailed plan by next Monday, April 23, 2012 so we can finalize our decision. To ensure we achieve the fastest path back to profitability and maintain transparency, please provide a quarter-by-quarter spending and deliverables roadmap that includes:\\n\\n\u2013 A clear breakdown of project milestones and the margin uplift you expect in each quarter  \\n\u2013 Contingency measures if any prototype extends beyond Q2, including alternate concepts or reallocation approaches  \\n\u2013 The stage-gate approval process you will use, with ROI or NPV thresholds defining go/no-go decisions  \\n\u2013 Any critical staffing or tooling shortfalls, and whether you\u2019ll need external consultants or special equipment  \\n\u2013 Key IP filing activities, regulatory dependencies, and expected lead times\\n\\nIf you can have this plan ready for our review by Monday, April 23, 2012, we\u2019ll schedule a follow-up meeting that same week to sign off on the funding launch. Let me know immediately if that timing presents any challenges or if you need further context.\\n\\nThanks in advance for pulling this together quickly. With a roadmap of this detail, I\u2019m confident we can drive Consumer Products back into profit within twelve months.\\n\\nBest regards,  \\n[Your Name]  \\nVP Finance, Hal & Scott Company\\n\\nI\u2019ll let you know as soon as any questions or updates come back.'}]"
    }
]